GlassScriptPhysician profile
Lauren Walliser
NPI 1023597341
$4,064.66
in general payments reported to CMS, 2019-2025
40 companies · $1,160 in 2025
The $1,160 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $898 · 2022: $613 · 2023: $537 · 2024: $856 · 2025: $1,160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,553.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $908.44 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $361.75 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $346.09 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $326.50 | 2021-2025 | Mounjaro, Jardiance, Reyvow |
| Otsuka America Pharmaceutical, INC. | $254.81 | 2021-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $248.25 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $207.73 | 2021-2025 | Trintellix |
| Axsome Therapeutics, INC. | $127.43 | 2024-2025 | Sunosi, Auvelity |
| Pfizer INC. | $127.10 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $126.21 | 2024-2025 | Ingrezza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $113.07 | 2021-2025 | Xifaxan, Trulance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $94.74 | 2024-2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $87.01 | 2021-2025 | |
| Abbott Laboratories | $63.61 | 2023-2024 | Freestyle Libre 2 |
| Lundbeck LLC | $63.50 | 2023-2025 | Rexulti |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Walliser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.